The Translational Breast Cancer Research Consortium was well represented at the 2023 SABCS Meeting. Presentations included:

AVIATOR/TBCRC 045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658); RF02-06

A Phase 2 Study of Stopping Trastuzumab in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC): the STOP-HER2 study (TBCRC 062)